Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,771.00
+1,379.49(+2.79%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

0.7206

0.0000

(0.00%)

At close: 09:30AM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	1.88B
Enterprise value	2.22B
Trailing P/E	17.13
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	1.04
Price/book (mrq)	0.60
Enterprise value/revenue	0.40
Enterprise value/EBITDA	-3.59

Trading information

Stock price history

Beta (5Y monthly)	N/A
52-week change ³	0.00%
S&P500 52-week change ³	22.38%
52-week high ³	0.7206
52-week low ³	0.7206
50-day moving average ³	0.7206
200-day moving average ³	0.7206

Share statistics

Avg vol (3-month) ³	N/A
Avg vol (10-day) ³	N/A
Shares outstanding ⁵	220.09M
Implied shares outstanding ⁶	3.36B
Float ⁸	479.3M
% held by insiders ¹	5.74%
% held by institutions ¹	1.18%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	11.93%
Dividend date ³	N/A
Ex-dividend date ⁴	24 May 2023
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Mar 2024

Profitability

Profit margin	-12.59%
Operating margin (ttm)	18.57%

Management effectiveness

Return on assets (ttm)	-0.41%
Return on equity (ttm)	-5.80%

Income statement

Revenue (ttm)	5.52B
Revenue per share (ttm)	3.76
Quarterly revenue growth (yoy)	5.60%
Gross profit (ttm)	N/A
EBITDA	205.42M
Net income avi to common (ttm)	-694.76M
Diluted EPS (ttm)	0.0400
Quarterly earnings growth (yoy)	133.00%

Balance sheet

Total cash (mrq)	2.5B
Total cash per share (mrq)	1.71
Total debt (mrq)	4.94B
Total debt/equity (mrq)	40.74%
Current ratio (mrq)	2.26
Book value per share (mrq)	8.23

Cash flow statement

Operating cash flow (ttm)	1.49B
Levered free cash flow (ttm)	1.14B